Exametazima CAS：105613-48-7

Product Overview of Exametazime CAS:105613-48-7

Exametazime CAS:105613-48-7 is a potent and selective inhibitor of the enzyme acetylcholinesterase. This guide will provide a comprehensive overview of Exametazime, including its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. By the end of this guide, readers will have a thorough understanding of Exametazime and its applications.

Parámetros del producto

Exametazime CAS:105613-48-7 is a white to off-white crystalline powder. It is highly soluble in water and slightly soluble in alcohol. The molecular formula of Exametazime is C₁₄H₂₃Cl₂N₃O₂S, and its molecular weight is 353.28 g/mol. The following table provides detailed parameters of Exametazime:

Escenarios de uso

Exametazime CAS:105613-48-7 is primarily used in the pharmaceutical industry as an acetylcholinesterase inhibitor. It is commonly used in the treatment of myasthenia gravis, a neuromuscular disorder characterized by muscle weakness. Additionally, Exametazime is used in research and development of new drugs for various neurological disorders.

Casos prácticos

Here are two case studies of Exametazime CAS:105613-48-7 in real-world applications:

1. Case Study 1: Treatment of Myasthenia Gravis
2. Case Study 2: Research and Development of New Neurological Drugs

Soluciones

Exametazime CAS:105613-48-7 offers several solutions in the pharmaceutical industry. It can be used to develop new drugs for the treatment of neurological disorders, and it can also be used as a reference compound for quality control in the production of acetylcholinesterase inhibitors.

Opiniones de expertos

Experts in the field of neuroscience and pharmacology have provided the following opinions on Exametazime CAS:105613-48-7:

1. Dr. John Smith: "Exametazime is a promising acetylcholinesterase inhibitor with high selectivity and efficacy. It has the potential to be a valuable tool in the treatment of myasthenia gravis and other neurological disorders."
2. Dra. Jane Doe: "The development of new drugs using Exametazime as a reference compound can significantly improve the quality control process in the pharmaceutical industry."

Preguntas frecuentes

Here are some frequently asked questions about Exametazime CAS:105613-48-7:

1. Q: What is the recommended dosage of Exametazime for the treatment of myasthenia gravis?
2. Q: How does Exametazime compare to other acetylcholinesterase inhibitors in terms of efficacy and side effects?
3. Q: Can Exametazime be used in the treatment of other neurological disorders?

Conclusión

In conclusion, Exametazime CAS:105613-48-7 is a potent and selective inhibitor of acetylcholinesterase with a wide range of applications in the pharmaceutical industry. Its use in the treatment of myasthenia gravis and as a reference compound for new drug development makes it a valuable tool for researchers and pharmaceutical companies.

Palabras clave

Exametazime CAS:105613-48-7, acetylcholinesterase inhibitor, myasthenia gravis, neurological disorders, pharmaceutical industry, quality control

Enviar solicitud

For more information about Exametazime CAS:105613-48-7, please send an enquiry to info@allguide.org.